Arrowhead Pharma, Sarepta TX ink new gene therapy deal
Arrowhead Pharmaceuticals (ARWR) has secured a new partnership with Sarepta Therapeutics (SRPT). Under the terms of the deal, Sarepta will pay Arrowhead $500 million upfront and make a $325 million equity investment to gain access to Arrowhead's gene silencing technologies,
Sarepta Therapeutics is paying Arrowhead Pharmaceuticals $500 million in cash, plus a $325 million equity investment, for ...
Sarepta Therapeutics said Tuesday that it will pay Arrowhead Pharmaceuticals $500 million in cash for a series of ...
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) shares are trading higher Tuesday after the company announced a global ...
周二，美银美林维持对Sarepta Therapeutics (NASDAQ:SRPT)的积极立场，重申"优于大市"评级，目标价为$200.00。该公司的乐观情绪源于Sarepta最近与Arrowhead达成的全球许可和合作协议，预计这将显著增强Sarepta的产品管线。
Don't Miss our Black Friday Offers: An announcement from Sarepta Therapeutics ( (SRPT)) is now available. Sarepta Therapeutics is undergoing a leadership change as Ryan Brown steps down, with ...
Analysts have set 12-month price targets for Sarepta Therapeutics, revealing an average target of $168.79, a high estimate of ...
Mutual of America Capital Management LLC cut its position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Free Report) ...
H.C. Wainwright analyst Mitchell Kapoor initiated coverage of Sarepta (SRPT) with a Sell rating and $80 price target The firm considers ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback